Lake Street lowered the firm’s price target on Tela Bio (TELA) to $3 from $6 and keeps a Buy rating on the shares following Q3 results that “were short of the Street” and 2025 and 2026 guidance that was down on prolonged sales force disruption. The firm believes shares could be range bound in the near-term, but also thinks the recapped balance sheet and reset outlook will “provide the team an opportunity to exceed expectations,” the analyst tells investors.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TELA:
- Strategic Initiatives and Financial Adjustments Underpin Buy Rating for TELA Bio Despite Short-term Challenges
- Tela Bio price target lowered to $4 from $7 at Canaccord
- TELA Bio’s Earnings Call: Growth Amid Challenges
- TELA Bio Secures $70M Loan for Growth Initiatives
- Tela Bio price target lowered to $1.25 from $2 at Piper Sandler